About Somatostatin receptor type 2
Somatostatin receptor type 2 (SSTR2) is a protein
from Homo sapiens identified by UniProt accession
P30874, 369 residues long.
MolForge cross-references it against 0 known binders and
345 disease associations.
Target properties
| Protein name | Somatostatin receptor type 2 |
|---|
| UniProt accession | P30874 |
|---|
| Gene | SSTR2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 369 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (8)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (345)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.61
- neuroendocrine neoplasm · score 0.61
- acromegaly · score 0.61
- carcinoid tumor · score 0.56
- carcinoid syndrome · score 0.56
- digestive system neuroendocrine neoplasm · score 0.54
- obesity · score 0.51
- cirrhosis of liver · score 0.50
- esophageal varices · score 0.49
- pituitary-dependent Cushing's disease · score 0.48
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P30874-F1 | alphafold | PREDICTED | 81.34 | — |
Amino-acid sequence (369 residues)
MDMADEPLNG SHTWLSIPFD LNGSVVSTNT SNQTEPYYDL TSNAVLTFIY FVVCIIGLCG NTLVIYVILR YAKMKTITNI YILNLAIADE LFMLGLPFLA MQVALVHWPF GKAICRVVMT VDGINQFTSI FCLTVMSIDR YLAVVHPIKS AKWRRPRTAK MITMAVWGVS LLVILPIMIY AGLRSNQWGR SSCTINWPGE SGAWYTGFII YTFILGFLVP LTIICLCYLF IIIKVKSSGI RVGSSKRKKS EKKVTRMVSI VVAVFIFCWL PFYIFNVSSV SMAISPTPAL KGMFDFVVVL TYANSCANPI LYAFLSDNFK KSFQNVLCLV KVSGTDDGER SDSKQDKSRL NETTETQRTL LNGDLQTSI
Explore Somatostatin receptor type 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets